Last reviewed · How we verify
NCT04290533
HD-tDCS Over the dACC in High Trait Impulsivity
NA trial testing Active High Definition transcranial Direct Current Stimulation (HD-tDCS) in Impulsive Behavior in 23 participants. Completed in 15 January 2020.
15 December 2019
Quick facts
| Lead sponsor | Monash University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | device feasibility |
| Enrollment | 23 |
| Start date | 4 March 2019 |
| Primary completion | 15 December 2019 |
| Estimated completion | 15 January 2020 |
| Sites | 1 location across Australia |
Drugs / interventions tested
- Active High Definition transcranial Direct Current Stimulation (HD-tDCS)
- Sham High Definition transcranial Direct Current Stimulation (HD-tDCS)
Conditions studied
- Impulsive Behavior — all drugs for Impulsive Behavior →
Sponsor
Monash University
Who can join
Adults 18 to 55, any sex, with Impulsive Behavior. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Psychological disorders characterized by impulsivity often show alterations in dorsal anterior cingulate cortex (dACC) activity. Recent research has therefore focused on non-invasive neurostimulation therapies for the modulation of functional activity in the dACC. To date there has only been one proof-of-concept study providing evidence for modulating dACC activity with non-invasive electrical neurostimulation (e.g. transcranial electrical stimulation). Since transcranial Direct Current Stimulation (tDCS) is relatively safe, tolerable, and mobile as compared to other neurostimulation techniques, it is worthwhile looking further into the effects of tDCS on functional dACC activity. The aim of the present research is to explore whether HD-tDCS can induce changes in the dACC in individuals with high trait impulsivity (N=20) in a double-blind cross-over study. Functional changes in dACC activity will be measured by the error related negativity (ERN), which is an event related potential generated by the dACC. The ERN is less pronounced in people that score high on impulsivity. It is therefore expect enhanced ERN amplitudes after HD-tDCS over the dACC. In addition, performance on the multisource interference task will be used as measure of dACC activity. It is hypothesize that increased dACC activity will be related to decreased impulsivity in high impulsive individuals as shown by improved inhibitory control on the Go/NoGo task. The results of the study may have implications for patient populations that are characterized by impulsivity.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04290533
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Impulsive Behavior
Currently open trials in the same condition.
- NCT06477029 — Examination of Transcranial Focused Ultrasound on Brain Activity in Adults · NA · recruiting
Other Monash University trials
Trials by the same sponsor.
- NCT07428473 — A Study of STX-1150 in Participants With Elevated Low-Density Lipoprotein Cholesterol (LDL-C) · Phase 1 · not yet recruiting
- NCT07300254 — Treponemal Shedding, Load, and Viability, in Women and Men-who-have-sex-with-women-only With Early Infectious Syphilis: · recruiting
- NCT06960967 — Effects of Chestnuts on Postprandial Glycaemic Response · NA · active not recruiting
- NCT07202078 — Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig) · Phase 2, PHASE3 · recruiting
- NCT07202091 — Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig) · Phase 2, PHASE3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04290533 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Monash University
- Last refreshed: 17 May 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04290533.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing